

Investor Presentation

NASDAQ:IMDX

September 2025

iMDxinc.com



Forward-Looking Statements

Safe-Harbor Statement

This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on the Insight Molecular Diagnostics, Inc.’s (iMDx) management’s beliefs and assumptions and on information currently available to management. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to the iMDx’s development and commercial model (including margin and cost, reimbursement, revenue and profitability, 1-3 year transplant commercialization strategy, strategic partnerships, market positioning and competitive advantage, scalability, capital efficiency, accelerated adoption and clinical development), anticipated timing of regulatory submissions and clearances, product development (including R&D pipeline, product launch and milestone opportunities), along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of iMDx’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests iMDx or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification.

iMDx has based these forward-looking statements largely on its current expectations and projections about future events and trends that iMDx believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, iMDx operates in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for iMDx’s management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the iMDx may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of iMDx, particularly those mentioned in the “Risk Factors” and other cautionary statements found in iMDx’s Securities and Exchange Commission (“SEC”) filings, which are available from the SEC’s website. Although iMDx’s management believes that the expectations reflected in its forward-looking statements are reasonable, the Company, the placement agent, and their respective representatives, cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company, the placement agent, and their respective representatives, undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


**Sending patient samples
across the country is a
waste of time.**

High Clinical Demand

Strong Reimbursement

IP Protected


Transplant Monitoring: \$2B Clinical Market in US Underpenetrated, Inefficient, Ripe for Disruption



Regulated
+ Reimbursed
+ Clinically Useful

Rapid Adoption

Why invest in molecular diagnostics?



High-value creation

Empowers doctors to reduce uncertainty to **make better decisions** to save lives. Enables researchers to measure biomarkers to **inspire innovation**.



High-value capture

Intellectual property protects our market position, commands high reimbursement rates, and therefore, may lead to **high margins and profitability**. Capital-light business model may deliver software-like gross margins.



High-quality recurring revenue

Once a standard of care is proven or adopted, customer **life-time value** often exceeds 30 years.

**Regulated transplant testing is a
\$1B+ greenfield global opportunity.**

Transplant strategic partner: Key terms

/ **BIO-RAD** Partnership

- Bio-Rad (NYSE: BIO) now a top five shareholder with **upfront equity investment** and **two subsequent** equity investments
- Coordinated rapid development of IVD platform
- At FDA clearance, exclusive negotiating period for Bio-Rad to acquire IVD commercial rights


Bio-Rad to help commercialize GraftAssure RUO

- Co-marketing in US and Germany, iMDx to act as commercial lead
- Bio-Rad exclusive commercial and distribution rights in rest of world

Accelerating Momentum

Announced publicly

Referenced in August shareholder letter



Experienced leadership Pioneering Molecular Diagnostics & Disruptive Growth



Josh Riggs
President & Chief
Executive Officer



**Ekkehard Schütz,
MD, PHD, FADLM**
Chief Science Officer



**Yuh-Min (Johnson)
Chiang, PHD**
Chief Technology
Officer



**Andrea
James**
Chief Financial Officer



Q

&

A

